Key facts
- It has raised $25.3M.
- Notable investors include Tech Incubator Program for Startup, Center for Creative Economy and Innovation, IMM Investment, Woori Venture Partners, NH Investment & Securities — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Inventera
- ·The full record, as it builds
Funding rounds
No funding rounds for Inventera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inventera
Developer of a biotech company designed to develop innovative imaging diagnostic contrast agents. The company's platform specialized in developing advanced magnetic resonance imaging contrast agents using patented technology, which utilizes a polysaccharide core and metal shell, its design aims to improve imaging resolution and biocompatibility, which could lead to significant advancements in medical imaging, providing clients with resolution magnetic resonance imaging contrast agents as well as computerized tomography and nuclear medicine contrast media.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 20
- Website
- inventera.kr/
- Ownership
- Privately Held (backing)
Inventera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inventera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inventera in its N-PORT filings yet. We sweep new filings monthly.